Pfizer contract links HHS to overseas prices

Newly disclosed federal documents show that the US Department of Health and Human Services (HHS) will receive a portion of increased revenue if Pfizer Inc. (PFE) is able to charge higher prices for certain drugs abroad. The revenue-sharing mechanism is set out in contract language that links HHS’s financial entitlement to gains from higher foreign prices, making the agency a direct beneficiary of increased overseas pricing.

The contract is described in the paperwork as a “most favored nation” agreement. While the specific pricing formulas remain partly redacted, the released language confirms that higher foreign prices for Pfizer products can translate into additional payments to HHS under the deal.

The contract materials were released by consumer watchdog group Public Citizen, which obtained them through a Freedom of Information Act lawsuit. The disclosures make public for the first time key terms of the Pfizer arrangement that had previously been withheld, although some financial details and formulas remain obscured.

In addition to the Pfizer contract, the released documents include agreements involving Eli Lilly & Co. (LLY) These materials provide a limited window into how the federal government structures certain drug-pricing arrangements with large pharmaceutical manufacturers.

The newly available contracts represent only a portion of a larger set of federal drug-pricing agreements. More than two dozen similar deals between the government and pharmaceutical companies remain confidential and were not fully disclosed in this document release.

Because many related contracts and some terms within the Pfizer and Eli Lilly (LLY) documents are still not public, the overall scope and financial impact of the broader set of arrangements cannot be fully assessed from the current materials. The disclosures nonetheless clarify that at least in Pfizer’s case, HHS stands to share in additional revenue if overseas prices rise under a “most favored nation” framework.